• Natera outlined a 35-study oncology data package scheduled for presentation at the 2026 ASCO annual meeting in Chicago on May 29-June 2.
• New colorectal cancer analyses are set to show that serial Signatera testing could identify patients more likely to benefit from post-surgery chemotherapy, while supporting reduced treatment for patients with sustained negative results.
• A planned real-world meta-analysis across multiple tumor types is expected to reinforce Signatera’s role as a broad recurrence-risk stratification tool, supporting wider adoption in routine monitoring.
• Additional presentations are slated to indicate that the company’s ultra-sensitive phased-variant approach can flag relapse earlier and that clearance signals align with favorable outcomes, strengthening the case for MRD-guided care pathways.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605211705BIZWIRE_USPR_____20260521_BW853793) on May 21, 2026, and is solely responsible for the information contained therein.